45+ years of senior executive medical industry leadership experience including Chairman, President and CEO of Becton, Dickinson and Company. Numerous Board roles, including; Boston Scientific, CVS, Aetna, AdvaMed (Chairman), Johns Hopkins Michael Bloomberg School of Public Health, Hackensack University Medical Center, College of Holy Cross, Columbia Business School, The Center for Higher Ambition Leadership. MBA Columbia University.
Edward Gillen is GRIP’s CEO and brings over 30 years medical device industry experience, including point-of-care diagnostics. Ed enjoyed a successful 23-year career at Becton Dickinson (BD) holding many positions globally including WW Senior Director – Strategy & Business Development – Diabetes Care Division, Global VP/GM – Surgical and Anesthesia Systems ($200M P&L), Advanced Drug Delivery, Global Business Leader – Vaccine Delivery. Ed’s startup experience includes his most recent role as CEO Medality Medical. Ed has his MBA from Penn State University.
Bruce Batten has over 30 years of General Management experience at Companies like BioRad, Thermo Instruments, CyberOptics and Advantek. In addition, he has participated in four technology startups at the C-level and was Founder/Co-Founder at two of the startups before founding GRIP. Bruce started his career in Academia earning a Ph.D. in Anatomy & Cell Biology at the Medical College of Virginia and did his post-doctoral work at Harvard Medical School. He’s held faculty positions at Harvard, Tufts and The Ohio State medical schools and later ran the MBA Program at Augsburg University. Bruce has over 10 years of molecular diagnostic development, including detailed work on a POC Zika virus assay. Bruce founded GRIP Molecular to commercialize breakthrough solid state bioelectronic technology that will disrupt the diagnostic industry and empower consumers and doctors with fast, accurate and comprehensive information.
Rich Minicus is GRIP’s Chief Financial Officer with over 30 years in M&A, venture capital investment, and capital markets transactions. Rich worked for 21 years in medical technology business development with Becton Dickinson (BD) and Pfizer, and for 9 years in commercial and investment banking with Merrill Lynch Capital Markets and JP Morgan. Rich gained venture capital experience with both BD Ventures and Merrill Lynch Venture Capital, where he invested in a wide variety of emerging medical technology and life science companies. Rich earned his MBA at Harvard Business School and holds an MS in Biology from Fairleigh Dickinson University.
Russell J. Penrose Professor in Nanotechnology Director, Minnesota Nano Center
Research Areas:
Graphene Biosensors
Biomedical & Biological Computational Methods
Energy Systems & Power Electronics
Micro and Nano structures
Kuhrmeyer Family Chair Professor, Mechanical Engineering
University of Minnesota
Research Areas:
3D printing functional materials & devices
Advanced manufacturing using nanoscale inks
Biomedical devices
Bioelectronics
Professor of Physics Boston College, American Physical Society Fellow, Lee Osheroff Richardson North American Science Prize
Research Areas:
Spectroscopic studies of novel solids, interfaces and nano-materials
Topological Insulators
Unconventional Superconductors
Spin/Valleytronics
Thermoelectrics
2D atomic crystals
Expert in Quantum Materials and Devices
Developed Cleanroom in a Glovebox
McKnight University Professor and Sanford P. Bordeau Chair in the Department of Electrical and Computer Engineering at the University of Minnesota
Research Areas:
B.S. in Physics from KAIST, Korea
Ph.D. in Applied Physics from Stanford University
Directs laboratory focusing on nanofabrication and biosensing
Research reported in over 160 journal publications
Fellow of Optica
University of Minnesota Regents Professor
McKnight Presidential Endowed Chair in Public Health
Author
University of Minnesota
Director of the Center for Infectious Disease Research and Policy (CIDRAP)
Distinguished Teaching Professor in the Division of Environmental Health Sciences, School of Public Health and Technological Leadership Institute, College of Science and Engineering,
Medical School – Adjunct Professor
Science Envoy for Health Security on behalf of the US Department of State 2018-19
Numerous national/global Advisory Board appointments on Biosecurity, Health Research and Pandemics
Stasia Ogden recently joined GRIP in a General Counsel role with a particular expertise in Intellectual Property Law. Stasia has over 20 years as a practicing attorney in law firms and major multi-national corporations and 9 years with Baxter Healthcare Corporation and 4 years with BD. Her focus on healthcare industry global IP strategy, transactions, licensing, litigation and global portfolio management will help GRIP navigate global IP issues and maximize existing rights to 3+ patent families that provide the foundation for GRIP’s novel electronic biosensor. Stasia has a Juris Doctor degree from Georgetown University, an MBA from University of Missouri – St. Louis, and a BA in Biochemistry from Northwestern University in Chicago.
Research Areas:
Research Areas:
Laurie Knutson is GRIP’s VP of Marketing. She bring over 30 years of healthcare strategy, product development and systems transformation experience across Fortune 50 to pre-revenue companies. Laurie has held C-level roles healthcare services, products, insurance, financial services and consulting, and was founder or C-level at 4 tech startups. Laurie’s focus on commercializing products in the healthcare sector is based on her unique ability to assess the market and product adoption variables in areas of unmet needs. Laurie also has 10+ years analytics with care model development for seniors, commercial and vulnerable populations. Laurie has her MBA in Finance from the University of Minnesota and her BA in Biology from St. Olaf College in Northfield, Minnesota.
Rich Minicus is seasoned Chief Financial Officer with over 30 years in M&A, venture capital investment, and capital markets transactions. Rich brings 21 years in medical technology business development with Becton Dickinson, BD Ventures, and Pfizer which has enabled GRIP to quickly formulate a detailed financial plan beyond what most startups provide to investors. Rich also has 9 years in finance with Merrill Lynch Capital Markets, ML Venture Capital, and JP Morgan. Rich earned his MBA at Harvard Business School, and holds a MS in Biology from Fairleigh Dickinson University.
Caroline Popper, MD is the Co-Founder and President, Popper & Co. healthcare consultancy. Caroline has the perfect combination of 30 years’ experience in medical diagnostics and drug discovery, combined with extensive direct clinical experience. She has held many senior managerial and advisory positions with numerous global diagnostics companies, including BD, bioMérieux and MDS Proteomics. Caroline was also an attending physician at the Department of Emergency Medicine at Baltimore’s Johns Hopkins Hospital, where she completed residencies in internal medicine and pathology.
Ed Gillen is GRIP’s CEO and brings over 30 years medical device industry experience, including point-of-care diagnostics. Ed enjoyed a successful 23-year career at Becton Dickinson (BD) holding many positions globally including WW Senior Director – Strategy & Business Development – Diabetes Care Division, Global VP/GM – Surgical and Anesthesia Systems ($200M P&L), Advanced Drug Delivery, Global Business Leader – Vaccine Delivery. Ed’s startup experience includes his most recent role as CEO Medality Medical. Ed has his MBA from Penn State University.
Bruce Batten has been founder / CEO of four technology startups including C-level roles at Thermo Instruments, CyberOptics and Advantek. Bruce started his career in Academia earning a Ph.D. in Anatomy & Cell Biology at the Medical College of Virginia, post-doctoral work at Harvard Medical School. He was Faculty member at Harvard, Tufts and The Ohio State medical schools and later ran the MBA Program at Augsburg University. Bruce has over 10 years of molecular diagnostic development, including detailed work on a POC Zika virus assay. Bruce founded GRIP Molecular to commercialize breakthrough solid state bioelectronic technology that will disrupt the diagnostic industry and empower consumers and doctors with fast, accurate and comprehensive information.